AG James Secures Another Agreement to Cap Insulin Prices for Uninsured New Yorkers

Cozen O'Connor
Contact
LinkedIn
Facebook
X
Send
Embed

Cozen O'Connor

  • New York AG Letitia James entered an agreement with Novo Nordisk Inc. to resolve an investigation into insulin marketing and pricing practices.
  • Under the terms of the agreement, Novo Nordisk will cap the price of their insulin products at $35 per monthly prescription for uninsured New Yorkers for a period of five years. The company also agreed to implement a streamlined process for notifying uninsured patients of their eligibility for the $35 monthly cap before they pay at the pharmacy counter and to continue providing free insulin to the highest-need consumers.
  • As previously reported, AG James reached similar price cap agreements with insulin manufacturers Eli Lilly and Company and Sanofi-Aventis U.S. LLC.
Send Print Report

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Cozen O'Connor | Attorney Advertising

Written by:

Cozen O'Connor
Cozen O'Connor
Contact
more
less

PUBLISH YOUR CONTENT ON JD SUPRA NOW

  • Increased visibility
  • Actionable analytics
  • Ongoing guidance

Cozen O'Connor on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign Up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide